ThromboTherapeutics Inc.

9:00 AM - 9:15 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
ThromboTherapeutics Inc. (TTI) is a medical therapeutics and diagnostics startup, founded in 2017 and based in Denver and Boston, working in partnership with the University of Colorado School of Medicine and the Massachusetts Institute of Technology. Our focus is on the treatment of bleeding and coagulation disorders, particular in the setting of traumatic injury, which results in 2.8 million hospitalizations and 214,000 deaths each year, in the U.S. alone.

Our flagship product, the tPA-Challenge™ assay repurposes the “clot busting” agent tPA to rapidly test the physiologic reserve of the patient’s coagulation system and predicts their risk of massive hemorrhage, allowing triage decisions to be made an hour faster than with existing tests. The tPA-Challenge™ has been validated in over 900 trauma patients, is being sold commercially for research use, and is shovel-ready for a pivotal trial/FDA approval.
Company Type:
Company Website:
Company HQ State:
Colorado
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Lead Product in Development:
tPA-Challenge™ In Vitro Diagnostic Assay
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Speaker
photo
CEO
ThromboTherapeutics Inc.